Multi-targeted therapy resistance via drug-induced secretome fucosylation
Cancer secretome is a reservoir for aberrant glycosylation. How therapies alter this post- translational cancer hallmark and the consequences thereof remain elusive. Here, we show that an elevated secretome fucosylation is a pan-cancer signature of both response and resistance to multiple targeted t...
Main Authors: | Mark Borris D Aldonza, Junghwa Cha, Insung Yong, Jayoung Ku, Pavel Sinitcyn, Dabin Lee, Ryeong-Eun Cho, Roben D Delos Reyes, Dongwook Kim, Soyeon Kim, Minjeong Kang, Yongsuk Ku, Geonho Park, Hye-Jin Sung, Han Suk Ryu, Sukki Cho, Tae Min Kim, Pilnam Kim, Je-Yoel Cho, Yoosik Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2023-03-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/75191 |
Similar Items
-
Role of Fucosylation in Cancer
by: Kun ZHANG, et al.
Published: (2016-11-01) -
Fucosylated Proteome Profiling Identifies a Fucosylated, Non-Ribosomal, Stress-Responsive Species of Ribosomal Protein S3
by: Gregory Watson, et al.
Published: (2021-05-01) -
The Impact of Dietary Fucosylated Oligosaccharides and Glycoproteins of Human Milk on Infant Well-Being
by: Magdalena Orczyk-Pawiłowicz, et al.
Published: (2020-04-01) -
Fucosylation in Urological Cancers
by: Kazutoshi Fujita, et al.
Published: (2021-12-01) -
Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation
by: Gabriele Antonarelli, et al.
Published: (2023-03-01)